Incidence of Genital Warts in Sweden Before and After Quadrivalent Human Papillomavirus Vaccine Availability
Open Access
- 18 July 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 206 (6) , 860-866
- https://doi.org/10.1093/infdis/jis405
Abstract
Background. More than 90% of genital warts (GW) cases are caused by human papillomavirus (HPV) types 6 and 11. The introduction of HPV vaccines necessitates the estimation of the population-based incidence of GW immediately before and after vaccination uptake. Methods. Incidence proportions were calculated using the entire population aged 10–44 years living in Sweden during 2006–2010. The Prescribed Drug Register and the National Patient Register were used to define GW episodes. Time trends were estimated using Poisson regression. Results. In 2010, age-stratified incidence proportions of GW were highest for 20-year-old women (956 cases/100 000), while the incidence proportion among males was greatest at the slightly older age of 24 years (1137 cases/100 000). Crude rates were marginally higher among males than among females during 2006–2007 and appeared to later diverge. Between 2008 and 2010, the overall incidence appeared to increase among males, and the incidence among females declined. Females aged 17 and 18 years had a >25% decline in GW rates between 2006 and 2010, with significant decreases through the age of 25 years. Conclusions. This study provides a reasonable estimation of the incidence of GW in the Swedish population by use of register data, with results comparable to those from previous smaller studies. There was a downward trend of GW incidence among younger females between 2006 and 2010.This publication has 23 references indexed in Scilit:
- The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programmeSexually Transmitted Infections, 2011
- Genital warts and cost of care in EnglandSexually Transmitted Infections, 2011
- Population Effectiveness, Not Efficacy, Should Decide Who Gets Vaccinated Against Human Papillomavirus via Publicly Funded ProgramsThe Journal of Infectious Diseases, 2011
- External review and validation of the Swedish national inpatient registerBMC Public Health, 2011
- Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance dataThe Lancet Infectious Diseases, 2011
- Incidence of anogenital warts in Germany: a population-based cohort studyBMC Infectious Diseases, 2010
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialBMJ, 2010
- Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young womenSexually Transmitted Infections, 2009
- The Swedish personal identity number: possibilities and pitfalls in healthcare and medical researchEuropean Journal of Epidemiology, 2009
- Type‐Specific Duration of Human Papillomavirus Infection: Implications for Human Papillomavirus Screening and VaccinationThe Journal of Infectious Diseases, 2008